Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate
Immunome Q4 Adj EPS $(0.15) Beats $(0.28) Estimate, Sales $3.83M Beat $2.07M Estimate
Immunome第四季度調整後每股收益美元（0.15美元）超過預期（0.28美元），銷售額383萬美元超過207萬美元的預期
Immunome (NASDAQ:IMNM) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.28) by 46.43 percent. This is a 76.56 percent increase over losses of $(0.64) per share from the same period last year. The company reported quarterly sales of $3.83 million which beat the analyst consensus estimate of $2.07 million by 84.83 percent.
Immunome（納斯達克股票代碼：IMNM）公佈的季度虧損爲每股0.15美元，比分析師普遍預期的0.28美元（0.28美元）高出46.43個百分點。這比去年同期每股虧損0.64美元（0.64美元）增長了76.56％。該公司公佈的季度銷售額爲383萬美元，比分析師普遍預期的207萬美元高出84.83％。